Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials — Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm
Open Access
- 1 September 2015
- journal article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 424, 43-52
Abstract
No abstract availableKeywords
Funding Information
- UK Department of Health
This publication has 46 references indexed in Scilit:
- Analysis of cytokine release assay data using machine learning approachesInternational Immunopharmacology, 2014
- Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody MultimerizationThe Journal of Immunology, 2014
- Induction of Interleukin‐6 Production by Rituximab in Human B CellsArthritis & Rheumatology, 2014
- Cell Contact–Dependent Priming and Fc Interaction with CD32+ Immune Cells Contribute to the TGN1412-Triggered Cytokine ResponseThe Journal of Immunology, 2014
- Enumeration and Characterization of Human Memory T Cells by Enzyme-Linked Immunospot AssaysJournal of Immunology Research, 2013
- Response to the Letter to the Editor by Susan Thorpe et al.: How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of responseCytokine, 2013
- How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of responseCytokine, 2013
- A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodiesJournal of Pharmacological and Toxicological Methods, 2013
- Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and ImmunotherapyImmunity, 2013
- After TGN1412: Recent developments in cytokine release assaysJournal of Immunotoxicology, 2012